Gelonghui reported on December 20 that Hefei Lifeon Pharmaceutical (003020.SZ) announced that recently, Hefei Lifeon Pharmaceutical Co., Ltd. received the approval notification for the listing application of the chemical raw material of Gatifloxacin issued by the National Medical Products Administration. Gatifloxacin is a cyclopropyl fluoroquinolone drug, a fourth-generation broad-spectrum antibacterial agent developed by the Japan-based Kyowa Kirin Co., Ltd., primarily used to treat various infectious diseases caused by sensitive pathogens.
立方制药(003020.SZ)：加替沙星原料药上市申请获得批准
Hefei Lifeon Pharmaceutical (003020.SZ): The application for the listing of the Active Pharmaceutical Ingredient Ceftazidime has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney